Stockscreener 앱 받기
1.83
28.87%
0.41
시장 영업 전:
1.98
0.15
+8.20%
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Insider Buying: Michael Alfieri Acquires Additional Shares of Al - GuruFocus
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock By Investing.com - Investing.com India
Aldeyra Therapeutics (ALDX) finance chief buys 5,000 shares - Stock Titan
What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities - GlobeNewswire
BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026 - Meyka
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky - Morningstar
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
HC Wainwright & Co. downgrades Aldeyra Therapeutics (ALDX) - MSN
Aldeyra’s CEO to Lead Strategic Discussions at Healthcare Conference - StocksToTrade
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) - The Globe and Mail
Aldeyra Eyes Growth as CEO Prepares for Key Conference - timothysykes.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Aldeyra Therapeutics, Inc. - 富途牛牛
ALDX Plummets 71% Following FDA's Third Complete Response Letter for Dry Eye Disease Drug Application - Bitget
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - Yahoo Finance
Upcoming Conference Sheds Light on Aldeyra Therapeutics’ Innovations - StocksToTrade
Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ALDX Stock Downgraded by HC Wainwright & Co. with Price Target R - GuruFocus
H.C. Wainwright cuts Aldeyra stock rating on FDA setback - Investing.com
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection - Yahoo Finance
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10 - marketscreener.com
FDA issues CRL to Aldeyra’s reproxalap drug application - Yahoo Finance
Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy DataHas The Bull Case Changed? - simplywall.st
FDA rejects Aldeyra’s dry eye disease drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalap - geneonline.com
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
Aldeyra Therapeutics stock plunges 70% after third FDA rejection - The Business Journals
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com
US FDA declines to approve Aldeyra’s eye disorder drug, shares slump - WSAU
Third Time Is Not The Charm For Aldeyra - Citeline News & Insights
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton ... - Bluefield Daily Telegraph
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For - GlobeNewswire
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm - GlobeNewswire Inc.
FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68% - MSN
Aldeyra plunges as FDA rejects dry eye disease therapy - MSN
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lacking Evidence, FDA Rejects Aldeyra Dry Eye Disease Drug - MedCity News
Why Aldeyra Therapeutics Stock Just Hit 52-Week LowAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Aldeyra Therapeutics Sees Unusually High Options Volume (NASDAQ:ALDX) - MarketBeat
Aldeyra collects third CRL for reproxalap in dry eye disease - BioWorld MedTech
FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings - Fierce Biotech
Aldeyra Therapeutics Shares Plummet Amid Financial Concerns - StocksToTrade
Aldeyra Therapeutics Receives FDA Complete Response Letter for Reproxalap Dry Eye Disease Treatment, No Additional Trials Required 1 - Minichart
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Aldeyra Therapeutics Shareholders Are Encouraged to Reach - GlobeNewswire
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting - BioSpace
Aldeyra Therapeutics (ALDX) Faces FDA Rejection for Dry Eye Drug - GuruFocus
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings - Benzinga
Aldeyra Therapeutics Sees Stock Movement Amid Latest Developments - timothysykes.com
US FDA declines to approve Aldeyra’s drug for eye disorder - KFGO
Aldeyra receives third complete response letter for reproxalap - Ophthalmology Times
FDA rejects Aldeyra’s dry eye disease drug application - Investing.com
Aldeyra (ALDX) Faces FDA Setback on Dry Eye Disease Drug Applica - GuruFocus
US FDA declines to approve Aldeyra's eye disorder drug, shares slump - marketscreener.com
Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns - marketscreener.com
Why Did ALDX Stock Tank 75% In Pre-Market Today? - Asianet Newsable
1.20%
0.06%
자본화:
|
볼륨(24시간):